ATE165976T1 - Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente - Google Patents

Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente

Info

Publication number
ATE165976T1
ATE165976T1 AT94910876T AT94910876T ATE165976T1 AT E165976 T1 ATE165976 T1 AT E165976T1 AT 94910876 T AT94910876 T AT 94910876T AT 94910876 T AT94910876 T AT 94910876T AT E165976 T1 ATE165976 T1 AT E165976T1
Authority
AT
Austria
Prior art keywords
permeability
bacreriacidal
administration
treatment
protein fragments
Prior art date
Application number
AT94910876T
Other languages
English (en)
Inventor
Lewis H Lambert Jr
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Corp filed Critical Xoma Corp
Application granted granted Critical
Publication of ATE165976T1 publication Critical patent/ATE165976T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT94910876T 1993-03-12 1994-03-11 Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente ATE165976T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3114593A 1993-03-12 1993-03-12

Publications (1)

Publication Number Publication Date
ATE165976T1 true ATE165976T1 (de) 1998-05-15

Family

ID=21857874

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94910876T ATE165976T1 (de) 1993-03-12 1994-03-11 Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente

Country Status (10)

Country Link
EP (1) EP0690721B1 (de)
AT (1) ATE165976T1 (de)
AU (1) AU6361894A (de)
CA (1) CA2157925C (de)
DE (1) DE69410254T2 (de)
DK (1) DK0690721T3 (de)
ES (1) ES2119185T3 (de)
GR (1) GR3027620T3 (de)
HK (1) HK1010983A1 (de)
WO (1) WO1994020129A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420019A (en) 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US6214789B1 (en) 1993-03-12 2001-04-10 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
AU7175694A (en) 1993-06-17 1995-01-17 Xoma Corporation Lipopolysaccharide binding protein derivatives
AU7330994A (en) * 1993-07-14 1995-02-13 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
US5770561A (en) * 1993-07-14 1998-06-23 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
PT759774E (pt) * 1993-09-22 2002-11-29 Xoma Technology Ltd Metodo para o tratamento de infeccoes bacterianas gram-negativas por administracao de um produto de proteina bactericida indutora da permeabilidade (bip) e de um antibiotico
US6759203B1 (en) 1993-09-22 2004-07-06 Xoma Corporation Method for quantifying BPI in body fluids
CN1133634A (zh) * 1993-09-22 1996-10-16 爱克斯欧玛公司 定量体液中的bpi的方法
ES2179095T3 (es) * 1994-01-14 2003-01-16 Xoma Technology Ltd Metodos y materiales anti bacterias gram positivas.
CN1112933C (zh) * 1994-01-14 2003-07-02 爱克索马技术有限公司 抗真菌的方法和物质
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US6271203B1 (en) 1994-07-07 2001-08-07 Xoma Corporation Anti-protozoan methods and materials
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
EP0839156A1 (de) * 1995-07-20 1998-05-06 Xoma Corporation Peptide gegen pilzbefall
ATE198050T1 (de) 1996-05-10 2000-12-15 Xoma Technology Ltd Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
JP2000511190A (ja) * 1996-05-23 2000-08-29 ゾーマ コーポレイション 外傷に起因する出血に見舞われたヒトにおけるｂｐｉタンパク質産物の治療用途
US5888973A (en) 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
NZ335401A (en) * 1996-11-01 2000-12-22 Xoma Corp Therapeutic uses of BPI protein products in cystic fibrosis patients
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6013631A (en) 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
EP1741440A1 (de) 2005-07-08 2007-01-10 Mellitus S.L. Verwendung von BPI-proteine zur Behandlung von stoffwechselbedingten Erkrankungen und Herzkreislaufstörungen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
EP0563222B1 (de) * 1990-12-03 1998-02-25 New York University Biologisch aktive bakterizide/permeabilitätserhöhende proteinbruchstücke

Also Published As

Publication number Publication date
ES2119185T3 (es) 1998-10-01
DE69410254D1 (de) 1998-06-18
AU6361894A (en) 1994-09-26
CA2157925A1 (en) 1994-09-15
HK1010983A1 (en) 1999-07-02
WO1994020129A1 (en) 1994-09-15
EP0690721A1 (de) 1996-01-10
CA2157925C (en) 2000-06-06
DK0690721T3 (da) 1999-03-08
EP0690721B1 (de) 1998-05-13
GR3027620T3 (en) 1998-11-30
DE69410254T2 (de) 1998-12-17

Similar Documents

Publication Publication Date Title
ATE165976T1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
DE69429527D1 (de) Inhibitoren von beta-amyloid-protein-herstellung
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
RU95108231A (ru) Glp-1-молекулярный комплекс, фармацевтическая композиция и способ получения комплекса
RU94038043A (ru) Применение замещенных производных аденина для лечения множественного склероза
EE03969B1 (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
IL110031A0 (en) Phenyl heterocycles, their manufacture and pharmaceutical compositions containing them
AU1679795A (en) Anti-fungal methods and materials
DK0858504T3 (da) Diagnostiske midler mod og behandlinger af periodontale sygdomme
ATE273279T1 (de) 2,3,5-trisubstituierte pyridine als inhibitoren von cyclooxygenase-2
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
NO972391L (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
FI972703A0 (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
ATE304371T1 (de) Verwendung von staphylococcus enterotoxin homologe für krebs-therapie
DE3584775D1 (de) Zusammensetzung zur behandlung von an haemophilia-a-inhibitor leidenden kranken.
ATE157010T1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
DK0722460T3 (da) Peptidderivater der er terapeutisk aktive i blodkoaguleringskaskaden, fremgangsmåde til fremstilling heraf og farmaceutiske
DK0707477T3 (da) Anvendelse af Efaxoran og derivater deraf til fremstilling af lægemidler beregnet til behandling af neurodegenerative sygdo
DE69626276T2 (de) Tetronsäurederivate zur behandlung von hiv- und anderen retroviruserkrankungen
UA29106A (uk) Спосіб лікування вібраційної хвороби
EP1015021A2 (de) Mittel gegen bakterielle meningitis
RU95107870A (ru) Способ лечения послеоперационной цилиохориоидальной отслойки
GEP19991605B (en) Inhibitor, Its Obtaining and Use

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee